Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5YK | ISIN: US57055L2060 | Ticker-Symbol: GX1
Frankfurt
06.06.25 | 08:07
1,180 Euro
+0,85 % +0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MARKER THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MARKER THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MARKER THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.Marker Therapeutics, Inc. - 8-K, Current Report4
20.05.Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma95Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive...
► Artikel lesen
19.05.Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies6
15.05.Marker Therapeutics, Inc. - 10-Q, Quarterly Report3
31.03.Marker Therapeutics GAAP EPS of -$1.19, revenue of $6.59M14
31.03.Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results136Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses...
► Artikel lesen
31.03.Marker Therapeutics, Inc. - 10-K, Annual Report2
27.03.Marker Therapeutics, Inc. - 8-K, Current Report4
MARKER THERAPEUTICS Aktie jetzt für 0€ handeln
19.02.Marker Therapeutics, Inc. - 8-K, Current Report3
11.02.Brookline Capital sets $4 target on Marker Therapeutics stock10
19.12.24Marker Therapeutics sells 5.03M shares at $3.20 in private placement3
19.12.24Marker Therapeutics meldet vielversprechende Ergebnisse in Lymphom-Studie3
19.12.24Marker Therapeutics reports promising lymphoma study results3
19.12.24Marker Therapeutics Announces $16.1 Million Private Placement9
19.12.24Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma157APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well...
► Artikel lesen
17.12.24Marker Therapeutics pops on receiving $9.5M grant to advance lead asset4
17.12.24Marker Therapeutics Awarded $9.5 Mln Grant From CPRIT For MT-601 In Metastatic Pancreatic Cancer2
17.12.24Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer3
17.12.24Marker Therapeutics receives $9.5 million grant for study3
17.12.24Marker Therapeutics, Inc. - 8-K, Current Report2
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1